145 related articles for article (PubMed ID: 20383593)
1. DCE-MRI detects early vascular response in breast tumor xenografts following anti-DR5 therapy.
Kim H; Folks KD; Guo L; Stockard CR; Fineberg NS; Grizzle WE; George JF; Buchsbaum DJ; Morgan DE; Zinn KR
Mol Imaging Biol; 2011 Feb; 13(1):94-103. PubMed ID: 20383593
[TBL] [Abstract][Full Text] [Related]
2. Breast tumor xenografts: diffusion-weighted MR imaging to assess early therapy with novel apoptosis-inducing anti-DR5 antibody.
Kim H; Morgan DE; Zeng H; Grizzle WE; Warram JM; Stockard CR; Wang D; Zinn KR
Radiology; 2008 Sep; 248(3):844-51. PubMed ID: 18710978
[TBL] [Abstract][Full Text] [Related]
3. Antitumor efficacy of TRA-8 anti-DR5 monoclonal antibody alone or in combination with chemotherapy and/or radiation therapy in a human breast cancer model.
Buchsbaum DJ; Zhou T; Grizzle WE; Oliver PG; Hammond CJ; Zhang S; Carpenter M; LoBuglio AF
Clin Cancer Res; 2003 Sep; 9(10 Pt 1):3731-41. PubMed ID: 14506165
[TBL] [Abstract][Full Text] [Related]
4. Effect of anti-DR5 and chemotherapy on basal-like breast cancer.
Oliver PG; LoBuglio AF; Zhou T; Forero A; Kim H; Zinn KR; Zhai G; Li Y; Lee CH; Buchsbaum DJ
Breast Cancer Res Treat; 2012 Jun; 133(2):417-26. PubMed ID: 21901385
[TBL] [Abstract][Full Text] [Related]
5. Early therapy assessment of combined anti-DR5 antibody and carboplatin in triple-negative breast cancer xenografts in mice using diffusion-weighted imaging and (1)H MR spectroscopy.
Zhai G; Kim H; Sarver D; Samuel S; Whitworth L; Umphrey H; Oelschlager DK; Beasley TM; Zinn KR
J Magn Reson Imaging; 2014 Jun; 39(6):1588-94. PubMed ID: 24151215
[TBL] [Abstract][Full Text] [Related]
6. Volumetric contrast-enhanced ultrasound imaging to assess early response to apoptosis-inducing anti-death receptor 5 antibody therapy in a breast cancer animal model.
Hoyt K; Sorace A; Saini R
J Ultrasound Med; 2012 Nov; 31(11):1759-66. PubMed ID: 23091246
[TBL] [Abstract][Full Text] [Related]
7. Low-molecular contrast agent dynamic contrast-enhanced (DCE)-MRI and diffusion-weighted (DW)-MRI in early assessment of bevacizumab treatment in breast cancer xenografts.
Moestue SA; Huuse EM; Lindholm EM; Bofin A; Engebraaten O; Mælandsmo GM; Akslen LA; Gribbestad IS
J Magn Reson Imaging; 2013 Nov; 38(5):1043-53. PubMed ID: 23908122
[TBL] [Abstract][Full Text] [Related]
8. A vasculature-targeting regimen of preoperative docetaxel with or without bevacizumab for locally advanced breast cancer: impact on angiogenic biomarkers.
Baar J; Silverman P; Lyons J; Fu P; Abdul-Karim F; Ziats N; Wasman J; Hartman P; Jesberger J; Dumadag L; Hohler E; Leeming R; Shenk R; Chen H; McCrae K; Dowlati A; Remick SC; Overmoyer B
Clin Cancer Res; 2009 May; 15(10):3583-90. PubMed ID: 19417018
[TBL] [Abstract][Full Text] [Related]
9. Assessment of early docetaxel response in an experimental model of human breast cancer using DCE-MRI, ex vivo HR MAS, and in vivo 1H MRS.
Jensen LR; Huuse EM; Bathen TF; Goa PE; Bofin AM; Pedersen TB; Lundgren S; Gribbestad IS
NMR Biomed; 2010 Jan; 23(1):56-65. PubMed ID: 19650073
[TBL] [Abstract][Full Text] [Related]
10. Early therapy evaluation of combined anti-death receptor 5 antibody and gemcitabine in orthotopic pancreatic tumor xenografts by diffusion-weighted magnetic resonance imaging.
Kim H; Morgan DE; Buchsbaum DJ; Zeng H; Grizzle WE; Warram JM; Stockard CR; McNally LR; Long JW; Sellers JC; Forero A; Zinn KR
Cancer Res; 2008 Oct; 68(20):8369-76. PubMed ID: 18922909
[TBL] [Abstract][Full Text] [Related]
11. Dynamic contrast-enhanced MRI evaluates the early response of human head and neck tumor xenografts following anti-EMMPRIN therapy with cisplatin or irradiation.
Kim H; Hartman YE; Zhai G; Chung TK; Korb ML; Beasley TM; Zhou T; Rosenthal EL
J Magn Reson Imaging; 2015 Oct; 42(4):936-45. PubMed ID: 25704985
[TBL] [Abstract][Full Text] [Related]
12. AG-013736, a novel inhibitor of VEGF receptor tyrosine kinases, inhibits breast cancer growth and decreases vascular permeability as detected by dynamic contrast-enhanced magnetic resonance imaging.
Wilmes LJ; Pallavicini MG; Fleming LM; Gibbs J; Wang D; Li KL; Partridge SC; Henry RG; Shalinsky DR; Hu-Lowe D; Park JW; McShane TM; Lu Y; Brasch RC; Hylton NM
Magn Reson Imaging; 2007 Apr; 25(3):319-27. PubMed ID: 17371720
[TBL] [Abstract][Full Text] [Related]
13. Heterogeneity of tumor vasculature and antiangiogenic intervention: insights from MR angiography and DCE-MRI.
Zhu W; Kato Y; Artemov D
PLoS One; 2014; 9(1):e86583. PubMed ID: 24466160
[TBL] [Abstract][Full Text] [Related]
14. Noninvasive evaluation of antiangiogenic effect in a mouse tumor model by DCE-MRI with Gd-DTPA cystamine copolymers.
Wu X; Jeong EK; Emerson L; Hoffman J; Parker DL; Lu ZR
Mol Pharm; 2010 Feb; 7(1):41-8. PubMed ID: 19958031
[TBL] [Abstract][Full Text] [Related]
15. Dual combination therapy targeting DR5 and EMMPRIN in pancreatic adenocarcinoma.
Kim H; Zhai G; Samuel SL; Rigell CJ; Umphrey HR; Rana S; Stockard CR; Fineberg NS; Zinn KR
Mol Cancer Ther; 2012 Feb; 11(2):405-15. PubMed ID: 22203731
[TBL] [Abstract][Full Text] [Related]
16. Multiparametric characterization of response to anti-angiogenic therapy using USPIO contrast-enhanced MRI in combination with dynamic contrast-enhanced MRI.
Kim J; Kim E; Euceda LR; Meyer DE; Langseth K; Bathen TF; Moestue SA; Huuse EM
J Magn Reson Imaging; 2018 Jun; 47(6):1589-1600. PubMed ID: 29205621
[TBL] [Abstract][Full Text] [Related]
17. Treatment of human colon cancer xenografts with TRA-8 anti-death receptor 5 antibody alone or in combination with CPT-11.
Oliver PG; LoBuglio AF; Zinn KR; Kim H; Nan L; Zhou T; Wang W; Buchsbaum DJ
Clin Cancer Res; 2008 Apr; 14(7):2180-9. PubMed ID: 18381960
[TBL] [Abstract][Full Text] [Related]
18. Analysis of the changes induced by bevacizumab using a high temporal resolution DCE-MRI as prognostic factors for response to further neoadjuvant chemotherapy.
Etxano J; Insausti LP; Elizalde A; López Vega JM; Plazaola A; Martínez P
Acta Radiol; 2015 Nov; 56(11):1300-7. PubMed ID: 25348477
[TBL] [Abstract][Full Text] [Related]
19. Early therapy evaluation of combined cetuximab and irinotecan in orthotopic pancreatic tumor xenografts by dynamic contrast-enhanced magnetic resonance imaging.
Kim H; Folks KD; Guo L; Sellers JC; Fineberg NS; Stockard CR; Grizzle WE; Buchsbaum DJ; Morgan DE; George JF; Zinn KR
Mol Imaging; 2011 Jun; 10(3):153-67. PubMed ID: 21496446
[TBL] [Abstract][Full Text] [Related]
20. R2* Relaxation Affects Pharmacokinetic Analysis of Dynamic Contrast-Enhanced MRI in Cancer and Underestimates Treatment Response at 7 T.
Kim J; Moestue SA; Bathen TF; Kim E
Tomography; 2019 Sep; 5(3):308-319. PubMed ID: 31572792
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
